Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Docetaxel resistance mechanisms

<< Previous

Bullboard Posts

Next >>

Comment by jeffm34on Sep 17, 2021 12:29pm

100 Views

Post# 33877814

RE:RE:Docetaxel resistance mechanisms

The other effect may be on Progranulin which binds to Sortilin.

"

Progranulin induces metastasis in breast cancer models"

Wino115 wrote: Nice find -- that's a great endorsement on two fronts. One, it once again documents how powerful taxanes are in stopping cancer cell --so we know this is a toxin the industry see's as highly effective if it can get in the tumor. Second, TH1902 is one of the three bioengineering methods needed to increase the effectiveness of the drug around resistance --using nanotechnology (the peptide) to enhance intracellular concentration. Nice endorsement!

jeffm34 wrote:
https://www.sciencedirect.com/science/article/pii/S0753332221006065

The article talks about EMT- mediated metastasis. I think there is a link with the Sortilin receptor and Progranulin.

"In addition, we have observed an increase in protein expression of the transcription factors SNAIL (SNAI2) and SLUG (SNAI1) in progranulin-treated breast cancer cell lines (Additional file 2) suggesting that progranulin also increase epithelial-mesenchymal transition (EMT) features of breast cancer cells."

Also from the original article are suggested ways to overcome docetaxel resistance.

" The final strategy is brining bioengineering to the help of biology. To date, different kinds of nanocarriers have been developed for delivery of DTX in cancer therapy and enhancing its intracellular accumulation"